Jordan: These 4 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Jordan

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Jordan: These 4 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can FYCOMPA (perampanel) generic drug versions launch?

Generic name: perampanel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Jordan Patent 2,832
Patent Title: بلورات مركب 2,1 ثنائي هيدروبيريدين وطريقة انتاجها (Crystals of 1,2-Dihydropyridine compound and their production process)

FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

When can YONDELIS (trabectedin) generic drug versions launch?

Generic name: trabectedin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Jordan Patent 2,464
Patent Title: صيغ تحتوي على اكتيناسيدين وسكريات ثنائية (Formulations comprising ecteinascidin and a disaccharide.)

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Jordan Patent 2,515
Patent Title: الشكل البلوري جاما لهيدروكلوريد الايفابراداين وعملية تحضيره والمكونات الصيدلانية المحتوية عليه (Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it)

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Jordan Patent 2,548
Patent Title: الشكل البلوري بيتا لهيدروكلوريد الايفابراداين وعملية تحضيره والمكونات الصيدلانية المحتوية علية (Beta Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it)

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.